Double-digit price hikes help Heinz and Reckitt post jump in value sales

Dettol maker says customers willing to accept increases on branded items, and that further rises on the way

The ketchup and baked beans group Kraft Heinz and Reckitt Benckiser, the maker of Dettol, Nurofen and Strepsils, have both revealed they hiked prices by double digits in the spring and that this helped to drive better-than-expected sales.

Heinz said prices rose by 12.4% in the three months to 26 June, helping it deliver a 10% rise in sales despite a 2.3% drop in the number of items sold.

The US-based food group which paused deliveries to the UK’s biggest supermarket, Tesco, this spring in a battle over price rises, said the inflation was “primarily driven by price increases to mitigate rising input costs”.

Sales are now expected to increase by more than 7% this year compared with about 5% previously anticipated. Miguel Patricio, Heinz’s chief executive, said the trading environment “remains fluid” but the company was now more resilient, and was “anticipating and adapting to changing market conditions” by managing inflation via pricing and efficiencies.

Reckitt hiked its prices by almost 10% in the three months to 30 June, saying customers were willing to accept increases on branded items and further rises were on the way.

Underlying sales for the group rose by nearly 12% in the second quarter of the year – ahead of expectations – as it also benefited from a 40% increase in demand for its baby formula in the US amid a nationwide shortage triggered by problems at rival Abbott Laboratories, which was forced to recall its products.

Reckitt swung to a pre-tax profit of £1.7bn after making a loss on the sale of brands in the year before, while its total sales rose just over 4% to £6.9bn for the half year.

The group now expects sales to rise by 8% for its financial year, up from a maximum 4% previously expected. Laxman Narasimhan, its chief executive, said: “Despite challenging conditions, we are confident about the rest of the year.”

Reckitt said sales had been strong despite a challenging environment in its supply chain “both in terms of logistical availability and certain raw material constraints”.

It added: “We continue to expect inflation on our cost of goods sold to remain in the high teens for the full year, based on current commodity pricing.”

The evidence of price rises at Reckitt comes after the maker of Marmite and Ben & Jerry’s, Unilever, said it had hiked prices by 11% in the spring and predicted growth for the year at the top end of expectations driven by further rises.

The hikes in brand names helped shop prices soar this month by the greatest amount since at least 2005, adding to pressure on households from rising energy bills and petrol prices.

Slough-based Reckitt said demand for baby formula in the US was likely to wane as Abbott’s product became available again but said it was expecting a long-term increase in sales of cold and flu products as Covid-19 became endemic.

While sales of the cleaning product Lysol fell significantly, revenues remained more than 50% above pre-pandemic levels as Reckitt said “consumers continue to exhibit elevated hygiene behaviours”.

Sign up to the daily Business Today email or follow Guardian Business on Twitter at @BusinessDesk

Matt Britzman, an equity analyst at Hargreaves Lansdown, said shoppers may not be thrilled by higher prices but he was impressed by Reckitt’s ability to sell more items despite the high rate of inflation.

“That’s testament to the defensive nature of Reckitt’s portfolio, cleaning and hygiene products are hardly going to be the first things left off shopping lists when wallets are stretched,” he said.

“Performance from key brands Dettol and Lysol continue to support the argument that increased hygiene awareness is here to stay. Sales may be down from last years astronomical highs, but both products look to be rebasing well ahead of pre-pandemic levels.”


Sarah Butler

The GuardianTramp

Related Content

Article image
KitKat to Dettol: UK consumers warned of further price hikes
Nestlé joins other firms in passing on rising costs, adding to financial squeeze facing UK households

Joanna Partridge

17, Feb, 2022 @3:33 PM

Article image
Dettol maker Reckitt Benckiser’s sales slow as it warns over prices
Consumer goods group, which also makes Nurofen and Durex, says its costs are rising

Joanna Partridge

27, Jul, 2021 @4:31 PM

Article image
Reckitt Benckiser upbeat despite emerging markets sales slowdown

Maker of brands including Dettol and Nurofen expects revenues to rise as firm increases sales of its 19 'powerbrands'

Sean Farrell

12, Feb, 2014 @1:44 PM

Article image
Reckitt Benckiser to pay $1.4bn fine over opioid treatment sales
Nurofen maker reaches deal with US over alleged fraudulent marketing of Suboxone

Sean Farrell

11, Jul, 2019 @8:36 AM

Article image
Denim, dresses and more affordable food help lift sales and profits at M&S
Retailer to restart dividend payments but warns of challenging year ahead as costs continue to rise

Sarah Butler

24, May, 2023 @4:27 PM

Article image
Does the Compass chief have enough time to get his hands dirty at Tesco?
Months after Richard Cousins quit Reckitt Benckiser amid other commitments, it’s hard to work out how he’ll put in a shift at Tesco

Nils Pratley

06, Oct, 2014 @12:03 PM

Article image
Boss of Dettol maker Reckitt Benckiser unexpectedly resigns
Laxman Narasimhan surprises investors by saying he will leave for US halfway through turnaround plan

Jasper Jolly

01, Sep, 2022 @11:11 AM

Article image
Reckitt Benckiser's sales warning is a product of mixed priorities | Nils Pratley
The previously lean machine behind Dettol and Durex has bet its future on branching out and scepticism is the right response

Nils Pratley

18, Oct, 2017 @6:33 PM

Article image
Reckitt Benckiser paid chief executive more than £23m last year
Rakesh Kapoor’s pay package almost doubled in 2015 because of a share-based bonus linked to company performance

Rob Davies

04, Apr, 2016 @12:37 PM

Article image
Reckitt Benckiser's $1.4bn settlement over Suboxone verges on the farcical | Nils Pratley
The UK company may have avoided a day in court, but its claims of innocence will never be tested

Nils Pratley

11, Jul, 2019 @6:57 PM